2,3,4-Trinitrobenzene-1-sulfonic acid | 31305-16-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4-Trinitrobenzene-1-sulfonic acid
• 英文别名: 2,3,4-trinitrobenzenesulfonic acid
• CAS: 31305-16-5
• 化学式: C6H3N3O9S
• 分子量: 293.17
• InChiKey: LIEVTTYXDCZXRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  200
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  [(4S,6R,9E,11R,12R)-11-[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-methyl-3-(methylamino)oxan-2-yl]oxy-4-[(4R)-2-oxo-1,3-dioxolan-4-yl]-5-oxatricyclo[8.3.0.04,6]trideca-1(13),9-dien-2,7-diyn-12-yl] 7-methoxy-5-methylnaphthalene-1-carboxylate 、 2,3,4-Trinitrobenzene-1-sulfonic acid 在 ice 作用下， 以 aqueous solution 、 碳酸氢钠 为溶剂， 反应 24.0h， 生成 硝基苯
  参考文献：
  名称：

  Neocarzinostatin derivatives and a process for manufacturing the same

  摘要：

  基本纯净的新卡因诺霉素抗癌药物的化学式为(A)：(SMA)-(NCS)-(SMA)(A)，其中(NCS)为二价的新卡因诺霉素残基，(SMA)包括重量平均分子量为800至2,500的苯乙烯-马来酸共聚物的单价残基，该(NCS)残基通过新卡因诺霉素分子的初级氨基与苯乙烯-马来酸共聚物的羰基形成的酰胺键与(SMA)残基结合。

  公开号：

  US04762885A1

文献信息

• LTA4H modulators and uses thereof
  申请人：Barchuk William T.

  公开号：US20080194630A1

  公开（公告）日：2008-08-14

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  白三烯A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的方法。
• Compositions for Targeted Delivery of siRNA
  申请人：Rozema David B.

  公开号：US20110207799A1

  公开（公告）日：2011-08-25

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内肝细胞的组合物。靶向RNAi多核苷酸与共靶向递送聚合物一起给予。递送聚合物提供膜穿透功能，用于将RNAi多核苷酸从细胞外运送到细胞内。可逆修饰为递送聚合物提供生理响应性。
• GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA
  申请人：Hadwiger Philipp

  公开号：US20120157509A1

  公开（公告）日：2012-06-21

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内细胞的组合物。与单独的靶向配体相比，药代动力学调节剂改善了体内靶向。靶向配体-药代动力学调节剂靶向基团靶向的RNAi多核苷酸可以单独或与共靶向递送聚合物一起在体内给予。
• [EN] 7-CARBOXYMETHYLOXY-3', 4', 5-TRIMETHOXY FLAVONE MONOHYDRATE, THE PREPARATION METHOD AND USES THEREOF<br/>[FR] MONOHYDRATE DE 7-CARBOXYMETHYLOXY-3',4',5-TRIMETHOXY FLAVONE, SON PROCEDE DE PREPARATION ET SON UTILISATION
  申请人：DONG A PHARM CO LTD

  公开号：WO2005023244A1

  公开（公告）日：2005-03-17

  The present invention relates to 7-carboxymethyloxy-3’, 4’, 5-trimethoxy flavone.monohydrate which is a non hygroscopic product suitable for the preparation of metered dose of 7-carboxymethyloxy-3’, 4’, 5-trimethoxy flavone having protective activity for gastrointestinal tract including the colon, and a preparation method and uses thereof. 7-carboxymethyloxy-3’, 4’, 5-trimethoxy flavone.monohydrate of the present invention has advantages such as mucus protecting activity for gastrointestinal tract including the colon, convenience for handling and storage under ordinary humidity owing to its non-hygroscopicity, and ability to contain an active compound consistently for the formulation production of a medicine. In addition, the preparation method of 7-carboxymethyloxy-3’, 4’, 5-trimethoxy flavone.monohydrate of the present invention reduces long steps of total synthesis and requires mild conditions for the production of a compound because autoclave condition is not necessary for methylation in this case, and makes mass-production possible without any purification process such as recrystallization or column chromatography.

  本发明涉及7-羧甲氧基-3'，4'，5-三甲氧基黄酮一水合物，这是一种非吸湿性产品，适用于制备具有对胃肠道包括结肠具有保护活性的7-羧甲氧基-3'，4'，5-三甲氧基黄酮的定量剂量，以及其制备方法和用途。本发明的7-羧甲氧基-3'，4'，5-三甲氧基黄酮一水合物具有诸如对胃肠道包括结肠的黏膜保护活性、由于其非吸湿性而在普通湿度下方便处理和储存的优点，以及能够持续包含活性化合物以便制剂生产药物。此外，本发明的7-羧甲氧基-3'，4'，5-三甲氧基黄酮一水合物的制备方法减少了总合成的长步骤，并且在这种情况下，对于甲基化不需要高压灭菌条件，因此在生产化合物时需要温和条件，并且可以实现无需任何纯化过程（如重结晶或柱层析）的大规模生产。
• [EN] AZASULFURYLPEPTIDE-BASED CD36 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS CD36 À BASE D'AZASULFURYLPEPTIDES ET UTILISATIONS DE CEUX-CI
  申请人：RSEM LTD PARTNERSHIP

  公开号：WO2016029324A1

  公开（公告）日：2016-03-03

  Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-mediated inflammatory disease, disorder or condition, and methods of obtaining such azasulfuryl-containing peptidomimetics, are also disclosed.

  揭示了能够抑制CD36活性的新型含氮硫酰基的肽类模拟物。还揭示了利用这些含氮硫酰基的肽类模拟物治疗与CD36相关的疾病、紊乱或状况，包括TLR2介导的炎症性疾病、紊乱或状况的用途，以及获取这种含氮硫酰基的肽类模拟物的方法。